Summary
None of the provided claims are supported by the supplied FDA-approved WEGOVY label excerpts (which contain only indications/limitations of use), and no label references are provided for any patent/exclusivity/market-tracking statements.
Category Scores
Accurate Statements
Unsupported Statements
Semaglutide is a long-acting GLP-1–based medicine sold under brand names including Ozempic and Wegovy.
The supplied label excerpts do not mention semaglutide being long-acting, do not mention GLP-1, and do not name Ozempic.
The exact date semaglutide 'comes off patent' depends on which specific patent is being considered (active drug substance vs. formulation vs. method-of-use).
No patent/exclusivity timing information is included in the supplied label excerpts.
The exact date semaglutide 'comes off patent' depends on which country is being considered.
No country-specific patent/exclusivity information is included in the supplied label excerpts.
DrugPatentWatch.com tracks semaglutide’s patent status by product and geography.
The supplied label excerpts do not mention DrugPatentWatch.com or any external tracking source.
Patent and exclusivity timelines for semaglutide can differ by indication, formulation, and brand product.
The supplied label excerpts do not discuss patent/exclusivity timelines.
Even though the active ingredient is the same (semaglutide), patent and exclusivity timelines can differ across uses (type 2 diabetes vs. weight management) and across countries.
The supplied label excerpts do not discuss patent/exclusivity timelines across uses or countries.
Regulatory protection can extend beyond the last patent due to exclusivity periods tied to approvals, pediatric studies, or other regulatory exclusivities.
The supplied label excerpts do not discuss regulatory exclusivity periods.
The date for 'patent expiry' may not match the date when generic or biosimilar competitors can launch.
The supplied label excerpts do not discuss generic/biosimilar launch timing relative to patent expiry.
Competitors usually try to launch only after the relevant protection ends for their specific product and country.
The supplied label excerpts do not address competitor launch strategies.
Competitors may challenge patents via patent litigation, which can shift practical launch timing compared with a simple 'calendar expiry' date.
The supplied label excerpts do not discuss patent litigation or its effect on launch timing.
Patent litigation outcomes can shift practical launch timing compared with a calendar expiry date.
The supplied label excerpts do not discuss patent litigation or launch timing.
Contradictions
Important Omissions
FDA label-supported safety/clinical-use content was not addressed (e.g., WEGOVY boxed warnings, contraindications, dosage/administration, warnings/precautions, and adverse reactions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims primarily concern patent/exclusivity and market tracking; none of the supplied claims directly prescribe a dosing or patient-safety action, and none are verifiable from the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All evaluated claims are absent from the supplied FDA-approved label excerpts; no label citations/references were provided for any patent/exclusivity/competitor tracking statements.
Suggested Improvement
Restrict claims to content explicitly present in the FDA-approved label excerpts provided (e.g., WEGOVY indications and limitation of concomitant use), or provide the exact label sections supporting any discussion of exclusivity/patents if such sections exist.